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Abstract: Gaucher's disease is a rare lipid storage disorder, affecting one in 40,000-200,000 people and results 
from a genetic deficiency of the enzyme glucocerebrosidase (glucosylceramidase ). We report a 10-year old 
Iranian girl with chief complaint of anemia from 8 years ago, managed for iron deficiency anemia. The patient 
had hepatomegaly associated with huge splenomegaly which was confirmed by sonography. No skeletal 
disorder was found. Bone marrow aspiration revealed typical Gaucher cells. Low level of P-glucocerebrosidase 
enzyme activity confinned the Gaucher disease. The patient is now under treatment with CEREZI1.1E, a 
recombinant DNA modified form of glucocerebrosidase with good condition. 
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INTRODUCTION 
Gaucher's disease is the most common lipid storage 
disorder known and results from a genetic deficiency of 
the enzyme glucocerebrosidase (glucosylceramidase). 
Enzyme deficiency results m accwnulation of 
glucocerebroside within the reticuloendothelial system. It 
may present with delayed stanturoponderal growth, a 
cutaneomucous pallor hepatosplenomegaly, bone marrow 
suppression and bone lesions (Rachid et al., 2005; 
Morales, 1996). The blood count formula showed anemia 
with major thrombocytopenia. The myelogram was poor 
and the osteomedullar biopsy showed the presence of 
Gaucher's cells. The diagnosis has been confirmed by 
enzymatic dosage (Leucocytar P-glucosidase). 
Gaucher's disease is classified into three types: type 1 
(non-neuronopathic), type 2 (acute neuronopathic) and 
type 3 (subacute neuronopathic). Of the three, type 1 is 
the most conunon, affecting one in 40,000-200,000 people 
and having a high prevalence among Ashkenazi Jews, 
affecting one in 450-1500 (Fumic et al., 2004). In 1991, 
enzyme treatment became available with the marketing of 
alglucerase, a placentally derived modified form of 
glucocerebrosidase. In 1994, a recombinant DNA modified 
form of glucocerebrosidase, known as imiglucerase, was 
developed to replace alglucerase. Most published data on 
enzyme therapy are with alglucerase in patients with 
type 1 disease. A dosage regimen of 60 units kg-1 every 
2 weeks for moderate to severe ill patients has been 
effective in reducing hepatosplenomegaly, improving 
anemia and thrombocytopenia, as well as improving 
weight gain and growth in children and increasing vigor 
and self-esteem in adults. Bone involvement is often slow 
to respond to therapy although pain is frequently 
improved. Controversy exists as to whether lower dosage 
regimens are as effective. The role of enzyme therapy in 
the rarer neuronopathic subtypes remams to be 
determined, but initial reports have been disappointing 
(Morales, 1996; Butters, 2007; Starzyk eta!., 2007). 
CASE REPORT 
The patient was a 10 year old girl, third 
child of her family, result of C/S. Their parents were 
non-consanguineous and healthy. Their ethnic was 
KORD, non-jewish and other child are healthy. Her mother 
didu't use any drug during this pregnancy. The patient 
managed for iron deficiency anemia for the firs two 
years of her life. Easy bruising and paleness with 
decreased appetite were her chief complaint on her first 
visit to oncologist on 1385/8/24. CBC was taken, 
revealed WBC ~ 4300 µL _, (N ~ 45%, L ~ 52%, E ~ 3%), 
RBC ~ 4,190,000µL-',Hb~10.9mg dL_,, MCV ~78.28 fl, 
Flt = 52,000 mL - 1. Biochemistry revealed calcium = 
9.1 mg dL-l and normal liver function. On physical 
examination, pale conjunctiva, clear lungs, Nl heart sound 
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Fig. 1: Bone marrow aspirate shows typical 
Gaucher cells ----+ 40 x view 
were found. No abnormal ophta1moscopic findings 
were found. N eurologic exam was normal. 
Anthropometric measures were: wt = 25 kg (< 25th 
percentile), Ht = 133cm(<10th percentile) andHc = 50.5. 
The liver edge was palpable 6 cm below the subxiphoid 
process and 4 cm below the right costal margin. Huge 
splenomegaly was also found. Other findings were 
n01TI1al. Liver parenchymawa<> n01TI1al in ultrasonography 
(US) and the liver s ize was 10 mm which was larger than 
normal. Also, hemogen and normal echo spleen was 
found with 184 mm length which was categorized as huge 
splenomegaly. Based on clinical and US findings, Bone 
Marrow Aspiration (BMA) was done for ruling out 
malignancy. BMA revealed moderate cellularity with 
normal eiythroid, lymphoid and myeloid series, but 
increa<>ed number of megakaryocytes and large lipid 
storage cells resembling Gaucher cells (Fig. 1 ). The 
diagnosis wa<> established by p-glucocerebrosida<>e 
activity level a<>say (1.4 mcmol/L/h, notmal: 2.1-5.3) in 
peripheral leukocytes which was done by the help of 
UNESCO organization in Argentina The patient is now 
under Enzyme Replacement Therapy (ER.1) by 
CEREZY1v!E with good condition. 
DISCUSSION 
Our case was referred by anemia and complete blood 
count showed bicytopenia and hepatosplenomegaly, 
confumed by abdominal sonography. Splenomegaly and 
bicytopenia were two important s igns with multiple 
differential diagnosis. Reticiloendothelial system 
hyperplasia, immune heperplasia, extramedullaiy 
hematopoiesis, intra or extracellular depositions and 
benign or malignant cellular infiltrations are the most 
causes ofsplenomegaly. On the other hand, primaiy bone 
marrow disease such as myelofibrosis, leukemia and 
lymphoma, also systemic disease such as hypersplenism, 
sarcoidosis, SLE and fol ate deficiency can potentially lead 
to cytopenia w ith cellular bone marrow. So, in order to 
approach to our case and rull-in causes, bone marrow 
aspintion was done, showed typical Gaucher cells 
(Kasperet al., 2005; Barton etaJ., 1991). 
Gaucher disease is mainly due to mutations in the 
gene-encoding acid P-glucosida<>e (GBA), located on 
chromosome 1 at position q21 (Phillip and Poplack, 1998). 
This disease severely impairs quality of life because of 
hematologic or skeletal complications, physical limitations 
and psychosocial problems for both patients and their 
families (Barnevel et al., 1983). Gauche1's disea<>e, type 1 
should be cons idered when unexplained spleno- and 
hepatomegaly, anemia, thrombocytopenia, or skeletal 
disease are present, particularly in combination. In our 
case, all of the so called s ings except skeletal problems 
were found. 
Lack of awareness and ofwidespread availability of 
the enzyme assay has as yet limited its application in 
clinical practice and led to many cases of Gauchet's 
disease being diagnosed by bone marrow and liver biopsy 
(Ch arrow et aJ., 2000). 
The diagnosis of Gaucher disease is established by 
an assay for P-glucocerebrosida<>e enzyme activity in 
peripheral leukocytes (Niederau and Haussinger, 2000). 
In our case, enzymatic diagnosis in dried blood spots 
on filter paper which has been previously discussed 
by Chamoles et al. (2002), showed serum level of 
1.4 mcmol/L/h (Normal range: 2.1-5.3) for the P-D­
glucosidase activity, which was lower than normal range. 
The treatment of type 1 Gaucher disease ha<> 
dramatically improved with the development of 
Enzyme Replacement Therapy (ERT) (Chamoles et al., 
2002). In previous studies, ERT has been shovvn to 
prevent progressive manifestations of Gaucher disease, 
as well as ameliorating specific features of the disease 
(Lin et al., 2006; Zimran et al., 1995; Weinreb et al., 2002). 
The study by Weinreb et al. (2002) found a 20-30% 
decrease in liver volume within 1-2 years after beginning 
ERT, with a reduction of30-40% by 5 years. 
A case report describes an experience of using 
recombinant enzyme by Masood and Ali (2006) in a child 
who was diagnosed as a ca<>e of Gaucher disea<>e at the 
age of 3 years. Regular enzyme replacement therapy has 
resulted in marked improvement in his hemoglobin level, 
absolute neutrophil count, plmelets and physical growth. 
In the study of Grigorescu Sido et al. (2007), enzyme 
replacement therapy administered for 18 months in 
Romanian patients with Gaucher disease type I led to a 
marked improvement in haematological parameters and 
hepato- and splenomegaly. In the majority of patients 
no further progress of bone disease was 
observed'. 
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Our patient suffered from hepatomegaly, with the 
liver edge palpable 6 cm below the subxiphoid process 
and 4 cm below the right costal margin before ERT, which 
we expect to decrease after treatment initiation. 
CONCLUSION 
Enzyme replacement therapy is available for the 
treatment of type 1 Gaucher's disease, resulting in clinical 
improvement with enhanced quality of life within the first 
year of treatment, although improvement in bone disease 
can take longer. Doses of 60 units kg-1 every 2 weeks are 
of clinical benefit to patients with moderate to severe 
disease. A number of lower dosage regimens have been 
evaluated in small groups of patients, with satisfactory 
clinical responses occurring in some of these patients. 
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